Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.37
−$0.30 · -3.46%
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Latest quote
$8.37
−$0.30 · -3.46%
After-hours
$8.37
$0.00 · 0.00%
Sep 10, 7:59 PM ET
Regular session · ET · Market data may be delayed.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Day range
Current $8.37
52-week range
Current $8.37
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
72
Undervalued
Sentiment
54
Mixed
Risk
50
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Day range
Current $8.37
52-week range
Current $8.37
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 175.11M USD | 55.25M USD | 682K USD | — | — |
| Cost of goods sold | 22.6M USD | 7.97M USD | 167K USD | 620K USD | 521K USD |
| Gross profit | 152.51M USD | 47.28M USD | 515K USD | −620K USD | −521K USD |
| Research and development | 32.78M USD | 34.08M USD | 49.9M USD | 71.44M USD | 72.34M USD |
| Selling, general, and administrative | 279.72M USD | 290.66M USD | 117.93M USD | 100.38M USD | 62.22M USD |
| Operating expenses | 312.5M USD | 324.75M USD | 167.83M USD | 171.82M USD | 134.56M USD |
| Interest income | 7.04M USD | 15.16M USD | 7.88M USD | 2.13M USD | 41K USD |
| Interest expense | 68.12M USD | 72.01M USD | 41.97M USD | 27.31M USD | 6.79M USD |
| Depreciation and amortization | 633K USD | 795K USD | 575K USD | 620K USD | 521K USD |
| Operating income | −159.99M USD | −277.47M USD | −167.31M USD | −172.44M USD | −135.08M USD |
| Net income | −221.25M USD | −334.33M USD | −201.59M USD | −197.72M USD | −143.88M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$17.60
110.27% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI17.57M0.00%2.3T USD0.03%$373.24-0.62%
iShares Russell 2000 ETFIWM10.82M0.01%80.51B USD0.19%$287.7-1.01%
State Street SPDR S&P Pharmaceuticals ETFXPH5.44M0.88%616.33M USD0.35%$68.01-1.89%
Vanguard Extended Market ETFVXF5.14M0.01%93.7B USD0.05%$236.16-1.05%
iShares Biotechnology ETFIBB3.8M0.04%10.73B USD0.44%$202.64-1.39%
iShares Russell 2000 Value ETFIWN2.86M0.02%14.61B USD0.24%$218.97-0.68%
Vanguard Russell 2000 ETFVTWO2.41M0.01%17.4B USD0.06%$116.34-1.00%
Simplify Propel Opportunities ETFSURI2.16M2.56%84.42M USD2.82%$19.4916-1.42%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOSimplify Propel Opportunities ETFSURIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
